HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.

AuthorsSai-Hong Ignatius Ou, Karen R Sommers, Michele C Azada, Edward B Garon
JournalThe oncologist (Oncologist) Vol. 20 Issue 2 Pg. 224-6 (Feb 2015) ISSN: 1549-490X [Electronic] England
PMID25568147 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Carbazoles
  • Piperidines
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • ACVRL1 protein, human
  • Activin Receptors, Type II
  • alectinib
Topics
  • Activin Receptors, Type II (genetics)
  • Adult
  • Carbazoles (administration & dosage)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, genetics, pathology)
  • Cerebellum (diagnostic imaging, pathology)
  • Crizotinib
  • Female
  • Humans
  • Meningeal Carcinomatosis (diagnostic imaging, drug therapy, genetics, pathology)
  • Neoplasm Staging
  • Piperidines (administration & dosage)
  • Pyrazoles (administration & dosage)
  • Pyridines (administration & dosage)
  • Radiography
  • Randomized Controlled Trials as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: